Alvesco®
Ciclesonide is a prodrug ICS activated in the lungs, minimizing systemic side effects. Used for prophylactic maintenance treatment of persistent asthma.
| Dosage Form | Inhaler (MDI) |
| Strength | 80 mcg, 160 mcg per actuation |
| Storage | Store at 25°C. |
| Category | Respiratory |
| Availability | Available for Transfer |
Persistent asthma (prophylactic maintenance, patients ≥12 years).
Prodrug converted to active desisobutyryl-ciclesonide (des-CIC) by esterases in the lungs. Des-CIC binds glucocorticoid receptors with high affinity, reducing inflammation with minimal systemic exposure.
Each Burrard Pharmaceuticals technology transfer package for Ciclesonide includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.